649bruno

Rollover Beethoven & Tell Tchaikovsky The News: PFE Rolling Over

Short
NYSE:PFE   Pfizer
4
In my opinion, Pfizer is about to drop. The chart above indicates a completed bearish butterfly harmonic pattern.
From my TRADE-MAP approach:
1. The Ichimoku Cloud is SINKING, with lower prices now (than structure to the left). 2. Prices are beginning another ROLLOVER, BEETHOVEN. 3. Prices are falling BELOW the thick red Ichimoku Cloud Conversion line. 4. The thick red conversion line is slowing. 5. The thick black line is the Ki-Jun-Sen baseline of the Ichimoku Cloud and this is beginning to slow down. 6. The indicator on the top of the page is RSI / Stochastic , and this is FAILING. 7. The top-side middle indicator is vortex and this is NEGATIVE (red over green). 8. The Top (bar-type) indicator measures the "phase energy", and this is beginning to go LOWER, with a probable negative zero line cross-over. This suggests the selling has quite a bit more to go. 9. The red fractal arrows (not pictured) are DOWN.
10. Look to the far right on the chart, between $32 and $34. You will notice a yellowish line on the top (jaws), with black dots below (teeth), and a blue line (jaw) below the black dots. Now, all three are BEGINNING TO CLOSE, correct? This is where I ask you to use your imagination and envision these three items as the "jaws, lips, and teeth of a REVERSING alligator, and the alligator will most likely feed into the DOWN-TREND as PFIZER does a ROLLOVER, BEETHOVEN.
The shorter term charts (15 minutes, one hour, four hours) are much more bearish as the selling picks up momentum.
With my apologies to Chuck Berry: "Roll over Beethoven - And tell Tchaikovsky the news, Pfizer may be dropping if you're long you will have the blues."
Today I will close with a quote from Alan Alda (Hawkeye on M*A*S*H): “It isn’t necessary to be rich and famous to be happy, it’s only necessary to be rich.”
I sincerely hope my contributions are helpful, entertaining, and save you money. May all of your trades go well. Don.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.